Exelixis, Inc. Said to Hire Goldman, Sachs & Co. to Field Possible Takeover Approaches; Shares Rise on Speculation

Bloomberg -- Exelixis Inc. (EXEL) is working with Goldman Sachs Group Inc. (GS) to prepare for potential takeover offers after its experimental drug helped prostate-cancer patients in a study, said people with knowledge of the matter.